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SumlTlary 
CD5 is a 67-kD glycoprotein that is expressed on most T  lymphocytes and on a subset of ma- 
ture B  cells.  Although  its physiologic  function  is  unknown,  several lines  of evidence  suggest 
that CD5 may play a role in the regulation ofT cell activation and in T  cell-antigen presenting 
cell interactions.  Using a CDS-immunoglobulin  fusion protein (CD5Rg, for receptorglobulin), 
we have uncovered  a  new  CD5  ligand  (CD5L)  expressed on the  surface of activated spleno- 
cytes.  Stimulation  of murine  splenocytes  with  anti-CD3  and  anti-CD28  antibodies  induces 
transient expression of CD5L on B lymphocytes that lasts for "72  h. Binding of CD5Rg to ac- 
tivated splenocytes is trypsin-resistant  and independent  of divalent cations.  However, it is pro- 
nase  sensitive  and  dependent  on  N-linked  glycosylation  of CD5,  since  treatment  of CD5Rg 
with PNGaseF or N-glycanase completely abrogates its ability to bind activated splenocytes.  In 
addition to splenocytes, CD5L is expressed on activated murine T  cell clones. Immunoprecipi- 
tation,  antibody,  and recombinant protein blocking studies indicate that CDSL is distinct from 
CD72,  which has been proposed to be a CD5 ligand.  To determine whether CD5-CD5L  in- 
teraction might play a role in vivo, we tested the effect of CD5Rg in a murine model of anti- 
body-mediated  membranous  glomerulonephritis.  Injection  of CD5Rg  was found  to abrogate 
development  of the  disease.  Taken  together,  our results  help  identify a  novel ligand  of CD5 
and propose a role for CD5 in the regulation of inmmne responses. 
C 
D5 is a 67-kD glycoprotein that is structurally related 
to the scavenger receptor cysteine-rich family (1), and 
expressed  on  thymocytes,  T  lymphocytes  and  subpopula- 
tions of mature and activated B  cells.  In particular,  autore- 
active B lymphocytes are observed to express CD5  (2)  and, 
at least in the mouse, the development ofCD5 + B  cells ap- 
pears  to  be  regulated  in  part  by  IL-10  (3).  The  precise 
physiologic function of CD5 has yet to be elucidated.  CD5 
may  play  a  significant  role  in  T  lymphocyte  activation, 
however,  based  on  observations  that  anti-CD5  antibodies 
can augment T  cell intracellular  calcium concentration  (4), 
proliferation  (5, 6),  and IL-2 release  (7,  8).  CD5  associates 
with  the TCR  ~ chain,  and is rapidly phosphorylated after 
ligation  of CD3/TCR  (9,  10).  Recently,  deletion  of the 
CD5  gene  was  shown  to  influence  the  development  of 
thymocytes in transgenic mice  (11).  In vivo, down-modu- 
lation  of CD5  by  mAb  induces  T  cell  unresponsiveness, 
and  is reported  to  prevent  experimental  autoimnmne  en- 
cephalomyelitis in the rat (12).  In addition,  anti-CD5  anti- 
body treatment  has a partial  therapeutic  effect on  collagen 
type  II-induced  arthritis  in  DBA/1  mice  (13).  Taken  to- 
gether,  these studies suggest that CD5  may play an impor- 
tant role in  transducing  signals  that are relevant  to  thymic 
development and to immune responses. 
Purified  biotin-labeled  CD5  has been proposed  to bind 
CD72/Lyb-2  on  both  human  and  routine  cells  (14,  15). 
CD72 is a type II glycoprotein of 42 kD that is costitutively 
expressed on  all cells  of the B  lymphoid  lineage,  with  the 
exception  of plasma  ceils,  and  engagement  of CD72  by 
mAb  induces  B  cell  activation  (16-18).  Thus,  it  appears 
plausible  that  the  proposed  interaction  between  CD5  and 
CD72  may  play  a  role  in  T-B  cell  cooperation  in  the 
course of an antibody-mediated immune response. 
In the present work, we have addressed the ability of sol- 
uble recombinant CD5 receptorglobulin  (CDSRg) 1 to rec- 
ognize ligands on the surface ofmurine  cells and its poten- 
tial  effect  on  murine  membranous  glomerulonephritis,  a 
model  of T-B  lymphocyte  interaction-dependent,  anti- 
body-mediated  disease  (19,  20).  Our  results  show  that 
tAbbreviations used in this paper: CD5L, CD5 ligand; CD5Rg, CD5 recep- 
torglobulin; RbAMBB, rabbit anti-mouse tubular brush border IgG. 
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activated  splenocytes,  and  that  it  can  prevent  antibody- 
mediated glomerulonephritis in vivo. 
Materials  and Methods 
Development and  Production of Soluble Recombinant Fusion Pro- 
teins.  Soluble receptor globulins were developed by genetic fu- 
sion of sequences  that encode the extracellular  region of human 
CD5 to genomic DNA sequences that contain exons that encode 
the hinge, CH2, and CH3 domains of human IgGi  as described 
(21). The plasmid containing sequences  encoding CD5Rg were 
introduced into CHO cells by electroporation at 250 V/960 txF 
in 4-ram  cuvettes  using a  gene  pulser  (Bio  Rad  Laboratories, 
1Lichmond,  CA).  Serum-free supernatants  were collected  5-7 d 
after  transfection,  and soluble  fusion proteins were  purified on 
protein A-Sepharose (PAS) as previously described  (21). A solu- 
ble CD8-hlg fusion protein previously shown to be nonreactive 
with nmrine tissues (22) was prepared using the same approach, 
and served as a control. Purified soluble fusion proteins were sub- 
jected to SDS/10% PAGE under reducing conditions and were 
analyzed after the staining of gels with Coomassie  blue. Soluble 
CD72 was prepared  and produced in COS cells as described (23). 
Splenocyte Preparation and Cell Lines.  For  splenocyte  prepara- 
tion,  BALB/c  mouse  spleens  were  sheared  through  a  90-lxm 
stainless steel  sieve,  and  cells were  pelleted  by  centrifugation. 
Erythrocytes  were osmotically lysed by incubation with 2 ml ster- 
ile distilled water for 3 s followed by rapid addition of 50 lnl PBS. 
After three washes in PBS, splenocytes  were cultured in ILPM1 
1640 (GIBCO BP,  L, Gaithersburg,  MD) supplemented with 5% 
heat-inactivated FBS (GIBCO BR.L). 
Four T cell clones were used: the l-Ek-restricted, conalbumin- 
specific Th2 clone D10.G4.1 and pigeon cytochrome C-specific 
Thl  clone AE.7  were purchased  from American Type Culture 
Collection  (Rockville,  MD).  The  I-Ad-restricted  Th2  clone 
CI)C25  specific  for  rabbit lgG  was  kindly provided by David 
Parker  (University of Massachusetts, Worcester, MA). The I-A  ~- 
restricted  Thl clone F1-28, specific for bovine myelin basic pro- 
tein, was kindly provided by Bob Clark (University of Connecti- 
cut, Hartford,  CT)  (24). The clones were cultured as previously 
described  (25). Each  of the  clones  was  stimulated  in 24  wells/ 
plate at a density of 0.5 X 10  ~' cells/well with 2 ￿  10  ~', 3,000 rad- 
irradiated  syngeneic splenocytes  in RPMI 1640 culture medium 
supplemented with 5% FBS, 50 b~M 13-mercaptoethanol,  20 U/ 
inl human rlL-2  (Hoffman-La Roche Ltd.,  Basel, Switzerland), 
and the appropriate  antigen. Conalbumin, cytochrome C  (Sigma 
Chemical Co., St. Louis, MO), and rabbit lgG (Cappel Laborato- 
ries, Downington, PA) were used at 10(1 Ixg/ml each. Myelin ba- 
sic protein (Sigma) was used at 20 Ixg/ml. 
Protease and Glycosidase Treatment.  To detemfine protease sen- 
sitivity of fusion protein interactions, cells were incubated with 
0.2% trypsin-I mM EDTA or 100 Ixg/ml pronase in PBS for 30 
min at 37~  and washed  before  testing their reactivity  with the 
fusion proteins.  To determine the potential role  of glycosylation 
of  CI)5  in  CD5-CD5L  interaction,  50  Ixg  of  PAS-purified 
CI)5tLg was subjected to PNGaseF (Oxford Glycosystems, Ox- 
ford,  UK)  hydrolysis  according  to  the  vendor's  recommen- 
dations.  Briefly,  20  U  of PNGaseF  was  used  to  deglycosylate 
50 Ixg of PAS-purified C1)5Rg for  18  h  at 37~  pH  7.5,  in a 
buffer provided by the vendor. Untreated and PNGaseF-treated 
CD5Rg were compared for mobility by SDS/PAGE after stain- 
ing of gels with Coomassie blue. 
Antibodies.  FITC-conjugated rat anti-mouse CD8a was from 
Biosource  (Camarillo,  CA); FITC rat  anti-mouse C1)4  and rat 
anti-mouse Thy 1.2, PE-conjugated rat anti-mouse B220,  puri- 
fied hamster  anti-mouse CD28, hamster  anti-mouse CD3 (145- 
2Cll), rat anti-mouse CD72, rat anti-mouse CD32, and CDI6 
(Fc~/II and III receptors)  and hamster  anti-mouse CD48  were 
from Pharmingen (San Diego, CA). Rat anti-mouse C1)2  (12- 
15) was a kind gift from Dr. P. Altevogt (Heidelberg,  Germany). 
FITC-conjugated goat  anti-rabbit IgG,  rabbit anti-mouse IgG, 
and rabbit anti-mouse C3 were purchased from Cappel. The goat 
anti-mouse IgG was absorbed  with rabbit IgG and its specifcity 
was confirmed by the absence of binding to kidneys of the mice 
killed  1 d after injection of rabbit anti-rat glomerular basement 
membrane antiserum (20), while staining with FITC goat  anti- 
rabbit IgG showed marked linear deposits  of rabbit IgG  on the 
glomerular basement membrane. 
Flolv C},tometry.  FACS  |  (Becton Dickinson & Co., Mountain 
View, CA)  analysis was performed on both splenocytes  and cell 
lines. To avoid nonspecific Fc receptor-dependent binding, cells 
were preincubated for 1 h at 4~  with 100 Ixg/ml purified mouse 
lgG (Cappel)  in PBS, washed,  and stained  with the appropriate 
reagents. The receptorglobulins were used at 5-10 Ixg/ml. For two- 
color analysis, splenocytes were first incubated with the receptor 
globulins for l h at 4~  washed, incubated with affinity-purified, 
FITC-conjugated goat  anti-human IgG  (Cappel)  preabsorbed 
with mouse, rat, and hamster serum, washed, and incubated with 
PE-conjugated mAbs recognizing distinct lymphoid lineages. 
Immunoprecipitation.  For metabolic  labeling, cells were  washed 
and incubated with methionine-free RPMI 1640 (GIBCO BILL) 
supplemented with  5%  dialyzed,  heat-inactivated  FBS  (Sigma) 
and appropriate  stinmlating  antibodies (anti-CD3 and anti-C1)28, 
anti-CD3 and anti-CD48, or anti-C1)3 alone),  and labeled with 
250  b~Ci/ml  [35S]methionine  (Amersham  International, Amer- 
sham, UK) for 12 h. Cells were then washed in PBS and lysed at 
4~  for 1 h in a lysis buffer containing 1% Triton X-l(10 (Sigma), 
10 I~g/ml leupeptin (Sigma), 100 U/ml aprotinin (Sigma), and 10 
mM  PMSF  (GIBCO  BRL,  Bethesda,  MD).  Nuclei  were  re- 
moved by centrifugation, and lysates were precleared by a l-h in- 
cubation with PAS CL4B  beads  (Pharmacia).  Lysates were then 
incubated with the soluble receptorglobulin for  1 h at 4~  PAS 
CL4B  beads were subsequently added,  and the incubation con- 
tinued for another hour. PAS beads were washed,  and inmmno- 
precipitates were eluted by boiling. Precipitated proteins were sub- 
jected to SDS/10% PAGE, the gels were fixed and dried, and the 
proteins were analyzed after exposure of gel for autoradiography. 
hlduction of Membranous  Glonten, lotwphritis and  7;h!atmet~t with 
CD5Rg.  8-9-wk-old C57B1/10  mice  were  purchased  fi-om 
Jackson Laboratories (Bar Harbor, ME). Membranous glomerulu- 
nephritis was induced in three groups of six animals each, as pre- 
viously described  (20). Briefly, all animals were mononephrecto- 
nnzed under sterile conditions and allowed to recover for at least 
3 wk.  On day 0 of the experiment, all animals were imnmnized 
with a single tail vein injection of rabbit anti-mouse tubular brush 
border  IgG  (RbAMBB),  prepared  as  previously  described  (2/)). 
From days 0-40,  the  three  groups  of mice were  injected eveu 
other day with 50 Ixg/ml of CD5Rg or C1)81-kg in 1511 Ixl of PBS 
or with 150 Ixl of PBS alone. All animals received  the first 1{I in- 
jections intravenously and the subsequent injections intraperito- 
neally,  and all were  killed  on day 40.  hnnmnofluorescence and 
electron microscopy studies of kidney sections, ELISA for detec- 
tion of mouse anti-rabbit IgG in the sera, FACS  |  analysis ofsple- 
nocyte populations, PBL  counts, and proteinuria measurements 
were performed as previously described  (20). 
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Figure  1.  Binding of CD5Rg 
to  mouse  splenocytes.  FACS  | 
analysis of (A) binding of control 
receptor globulin CD8Rg to un- 
stimulated splenocytes (a compa- 
rable FACS  |  profile was obtained 
using activated splenocytes, data 
not  shown);  (B)  binding  of 
CD5Rg to unstimutated spleno- 
cytes and  to  splenocytes stimu- 
lated  for  24  h  with  anti-Cl)3 
mAb alone (C) or anti-CD3 plus 
anti-CD28 mAbs (D). 
Statistics.  Statistical  analysis, when applicable, was performed 
using Statview IV software (Abacus  Concepts, Berkeley, CA) on 
a  Macintosh  SE  computer  (Apple  Computer,  Inc.,  Cupertino, 
CA).  Differences between  groups  were  compared by  one-way 
analysis of variance and unpaired Student's t test. 
Results 
CD5Rg  Recognizes a Ligand on Activated Murine  Spleno- 
rites  To test the ability of CD5 to recognize putative cell- 
surface  ligands,  resting  and  activated  routine  splenocytes 
were incubated with CD5Rg,  and specific binding was as- 
sessed  by  FACS |  analysis.  Binding  of CD5Rg  to  resting 
and anti-CD3  antibody-activated splenocytes was minimal 
or  absent  (Fig.  1).  However,  CD5Rg  bound  splenocytes 
triggered  with  a combination  of anti-CD3  and anti-CD28 
antibodies  at a concentration  of 5  lxg/ml each. Binding  of 
CDSRg to splenocytes was observed from  12 to 72 h  after 
anti-CD3/CD28  stimulation,  but was not detectable there- 
after. Similar CD5Rg  binding was observed to splenocytes 
costimulated  with  anti-CD3  and  anti-CD48  antibodies 
(data  not  shown).  Interestingly,  two-color  FACS |  analysis 
revealed that  CD5Rg  binding was confined  to the B220 + 
cell population  (Fig. 2). 
Binding assays were performed after preincubation  of the 
splenocytes  with  100  txg/ml  of purified  mouse  IgG  and 
with  100  Ixg/ml  of anti-CD16  and  anti-CD32  Fc  recep- 
tor-blocking  rnAbs  to  minimize  Fc  receptor-dependent 
binding.  Soluble  human  CD8Rg,  Fas-Rg,  and  CD44Rg 
(22),  used as negative controls,  failed to bind activate sple- 
nocytes,  while  mouse  CTLA4-Rg  (25),  used  as a positive 
control,  bound  splenocytes  as  expected  (data  not  shown). 
CD5Rg  binding was not  significantly altered  by the  pres- 
ence  of 10  mM EDTA  or by pretreatment  of splenocytes 
with trypsin (Table 1). In contrast, treatment ofsplenocytes 
with  pronase  totally  abrogated  CD5Rg  binding,  as  did 
treatment of CD5Rg with PNGase-F or N-glycanase, which 
cleave N-linked glycans (Table  1). 
Activated Splenorite CD5L is Distinct  fiom CD72.  The  T 
and  B  cell-surface  receptor  CD72,  which  is constitutively 
expressed on splenocytes, has been proposed to be a ligand 
of CD5  (14,  15).  To  determine  whether  the  observed 
binding of CD5Rg  to activated splenocytes is mediated by 
CD72, possibly altered by activation-associated posttransla- 
tional  modifications,  activated splenocytes were pretreated 
with  the  anti-CD72  mAb  clone  10-1.D.2,  which  is  re- 
ported  to  prevent  CD5-CD72  interaction,  at a  saturating 
concentration  (100  btg/0.5  ￿  106  cells/n'd).  Neither  the 
anti-CD72  rnAb  nor  preincubation  of the  minimal  con- 
centration  of CD5Rg required to detect binding (5  Ixg/ml) 
with  excess  recombinant  CD72-CD8  fusion  protein  (23) 
had any effect on CD5Rg  binding to activated splenocytes 
(Fig. 3). 
Binding of CD5Rg to Murine T Helper Clones.  To  further 
assess  CD5 ligand expression, AE-7  (Thl),  CDC25  (Th2), 
FI-28  (Thl),  and  D10.G4.1  (Th2)  nmrine  culture--propa- 
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Figure 2.  B cells express CD5L after splenocyte stimulation with anti- 
CD3 and anti-CD28 mAbs. Two-color  FACS  ~ analysis of splenocytes 
costimulated for 24 h with anti-CD3 plus anti-CD28 mAb and stained for 
B220 expression (vertical axes) and for CD8Rg (A) and CI)5Rg (B) bind- 
ing (horizontal axes). 
gated T  helper cell clones were tested for CD5Rg binding. 
Each of the clones was stimulated with irradiated APCs and 
antigen and cultured in IL-2. CD5Rg was observed to bind 
to all four cell lines  10-12 d after stimulation  (Fig. 4). The 
cells maintained  the ability to bind CD5Rg for 3-4 d, but 
lost it thereafter (data not shown).  The features of CD5Rg 
binding to the T  cells were assessed on the AE-7 clone and 
appeared  to  be  comparable  to  those  associated  with  acti- 
vated  splenocyte  binding  with  respect  to  divalent  cation 
independence,  trypsin  resistance,  pronase  sensitivity,  and 
CD72 unrelatedness  (Fig. 5 and data not shown). 
CD5Rg hnmunoprecipitates  a 35-37-kD  CD5L on Activat- 
ed Splenocytes  and T  Cell Clones.  To characterize the puta- 
tive  CD5L,  radiolabeled  lysates  from  anti-CD3/CD28 
antibody-activated splenocytes were subjected to immuno- 
precipitation  by CD5Rg.  A  single  35-37-kD protein  was 
Table  1.  Characterization of CD5Rg Bindi,g to Splenocytes amt 
the AE. 7 T  Cell Clone 
Treatment  Splenocytes  AE.7 
CD8Rg  -  - 
CD5Rg  + +  + + 
CD5Rg +  EDTA  + +  + + 
CD5Rg +  Trypsin  +  + + 
CD5Rg +  Pronase  -  - 
CD5Rg +  PNGase-F  -  - 
CD5Rg +  N-glycanase  -  - 
Mean fluorescence intensity (MFI) as a reflection of receptorglobulin 
binding is graded as follows: (+) MFI <15, weak binding; (++)  15 
>MFI <100, intermediate binding; (+ + +) MFI >100, strong binding. 
observed to be inmmnoprecpitated by CD5Rg (Fig.  6 A). 
Expression  of this  protein  was  consistent  with  activated 
splenocyte  reactivity  with  CD5Rg.  hnmunoprecipitation 
of the protein was obtained only from lysates of day 1 to 2 
anti-CD3/CD28  antibody-activated  splenocytes.  CDSRg 
failed to precipitate the 35-37-kD polypeptide or any other 
protein  species  from the  lysates  of resting splenocytes and 
of cells  that  had been  activated  more  than  3  d  previously 
(Fig.  6  A).  PNGaseF  treatment  of CD5Rg  abrogated  its 
ability  to  imnmnoprecipitate  the  35-37-kD  polypeptide 
from activated splenocyte lysates (Fig. 6 B), and CHO  cell- 
derived  CD44Rg  displayed  no  reactivity  with  activated 
splenocytes (data not shown). Taken together, these obser- 
vations support the notion that appropriate glycosylation of 
CD5,  and  not  the  Ig portion  of the  fusion  protein,  is  re- 
quired  for CDSL  recognition.  Immunoprecipitation  of T 
cell clone-derived lysates by CD5Rg revealed a similar 35- 
37-kD species (data not shown). 
CD5Rg  Inhibits  the  Development  of Murine  Membranous 
Glomerulonephritis,  an Immune Complex-mediated  Disease  that 
Requires T-B Cell Interaction.  To  determine  whether  the 
observed CD5-CD5L interaction might play a role in T-B 
cell interaction  in vivo, we administered  CD5Rg to mice 
in which development of antibody-mediated membranous 
glomerulonephritis had been induced. 
The  nmrine  antibody-mediated  model  of membranous 
glomerulonephritis  was  first  described  by  Assmann  et  at. 
(19),  and its  dependence  on T-B cell interaction  has been 
clearly  established  (20).  MGN  was  induced  in  monone- 
phrectomized  C57B1/10  mice  according  to  a  previously 
developed  strategy  (20).  On  day  0  of the  experiment,  all 
animals  were  immunized  with  a  single  intravenous  injec- 
tion  of 7.5  nag RbAMBB,  which  among  other  antigens, 
recognizes dipeptidyl pepdidase IV (DPPIV) on the surface 
of glomerular podocytes. Binding of RbAMBB to DPPIV 
on  podocytes  results  in  local  shedding  of immune  con> 
plexes  which,  in  the  absence  of an  autologous  immune 
response,  are  eliminated  by  local  clearing  mechanisms. 
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Figure 3.  Binding of CD5Rg to 
splenocytes is CD72  independent. 
Staining  of  activated  splenocytes 
was  performed  with  control 
CD8Rg  (A),  with  CD5Rg  (B), 
with  CD5Rg  after  preabsorbtion 
of the cells  with anti-CD72  mAb 
(C),  or with CDSkg after preab- 
sorbtion  of the  receptor globulin 
with  soluble  CD72-CD8  fusion 
protein (D). 
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Figure  4.  Activated murine T  cell clones 
bind  CD5P~g.  Murine  T  cell  clones were 
stimulated for 12 d as described in Materials 
and Methods and incubated with PBS (solid 
line),  CDSRg  (dotted  line),  or  CD5Rg 
(dashed  line),  followed by an  FITC-labeled 
goat anti-human lgG. 20{~ 
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Figure 5.  Binding of C1)SR.g to the AE.7 T cell clone is CD72 inde- 
pendent.  Staining of activated AE.7 ceils was  performed with  control 
CI)SRg (solid lira') and with CD5P, g (A,  dotted lira,), C1)SRg after preab- 
sorbtion of the cells with anti-CD72 mAb  (B, dotted line), or CD5P-g after 
preabsorbtion of the  receptorglobulin with  soluble CD72-CD8  fusion 
protein (C, dotted line). 
However, the mouse immune response to rabbit immuno- 
globulins results in the binding of mouse antibodies to rab- 
bit Ig and  local deposition and in fixation of the  immune 
complexes. 
Mice in the experimental groups were injected on alter- 
nate  days, from  day 0  to  day 40,  with  50  Dg CD5Rg  or 
CD8Rg  in  150  ILl PBS  or with  150  txl PBS  alone. All of 
the ,nice received the first 10 injections intravenlously and 
the  subsequent  injections  intraperitoneally.  All  animals 
were killed on day 40, and renal tissue was subjected to ex- 
amination by fluorescence and electron microscopy. 
Figure 6.  (A) lmnmnoprecipitation of  a candidate CI)SL. lmnmnopre- 
cipitation by Ct)8Rg (lanes A, C, and E) and by Cl)5P,  g (lanes B, D, and 
/z)  from lysates of 3"~S-radiolabeled  resting (lanes A and  B),  24-h  anti- 
Cl)3/anti-CD28-activated (lanes C  and  D)  and 96-h  anti-CI)3/anti- 
CD28-activated splenocytes (lanes E and F). (B) Abrogation of immuno- 
precipitation  of  the  candidate C1)SL after PNGAseP  treatment  of 
CI)SP,.g. Reagents  used and  their  treatment  are  indicated.  Molecular 
weight markers are shown on the right. 
Mice injected with  RbAMBB  and treated with  PBS  or 
CD8Rg  developed diffuse  granular  deposits of rabbit and 
mouse IgG in glomerular peripheral capillary walls (Fig. 7). 
Granular  deposits  of rabbit  IgG,  with  small  amounts  of 
mouse  IgG,  were  also  present  along  the  basement  mem- 
branes of proximal tubules and in Bowman's capsule. Elec- 
tron microscopy revealed small dense  deposits in  the  sub- 
epithelial part of the  glomerular basement membranes  and 
"spikes"  similar to  those  seen  in  human  MGN  (data  not 
shown).  Mesangial deposits were  comparable to  those  ob- 
served in untreated mice. Antibodies to rabbit lgG became 
detectable in the serum of these mice on day 7  and reached 
a  peak  on  day  21  (Fig.  8).  In  mice  mmmnized  with 
RbAMBB and treated with CD5P, g, tissue examination by 
immunofluorescence  and  electron  microscopy  revealed 
normal  glomerular  peripheral  capillary  walls  (Fig.  7  and 
data not shown).  Some residual granular deposits of rabbit 
IgG were  found  in  the  basement  membranes  of proximal 
tubules and in Bowman's capsule, consistent with previous 
observations  (20).  Staining for  mouse  lgG  and  C3  in  the 
mesangium  did  not  differ  appreciably  from  that  seen  in 
control mice  (data not shown).  During the first 3  wk a*~er 
immunization, mouse anti-rabbit IgG antibody levels were 
significantly lower than  in PBS or CD8P, g-treated animals 
(Fig. 8). Receptorglobulin treatment did not result in rood- 
816  A Novel CD5 Ligand Figure  7.  lnmmnofluorescence 
microscopy  of  glomeruli from  a 
C57B1/10  nlouse injected with 
RbAMBB and treated for 40 d with 
CD8Rg (a and c) or with CD5Rg (b 
and  d).  (a)  Granular deposits  of 
mouse IgG in the peripheral glomer- 
ular capitlary walls; (b)  Absence of 
detectable mouse IgG in glomeruli 
of animals treated with CD5Rg. (c) 
Diffuse, granular deposits of rabbit 
lgG  in  the  peripheral glomerular 
capilla  W walls; coarse deposits are 
also present in the  mesangium. (d) 
Absence of rabbit IgG  deposits in 
glonmrular capillary walls; some re- 
sidual IgG is present in the tubules 
and  the  Bowman's capsule, a-d, 
￿  400. 
ifications in peripheral blood leukocyte numbers, nor did it 
alter the  composition of lymphocyte subpoputations (data 
not shown). 
Discussion 
In the present work, we provide evidence of the  exist- 
ence of a  cell-surface CD5  ligand (CD5L)  that is  distinct 
from  CD72.  Soluble CD5Rg is  shown to  bind CD5L  in 
splenic B  cells 1-3 d after stimulation of splenocytes with a 
combination of anti-CD3  and  anti-CD28  antibodies.  It 
recognizes CDSL  on Thl  and  Th2  clones  10-12  d  after 
stimulation with antigen in the presence of APC and IL-2. 
Our  present  observations do  not  distinguish between  de 
novo expression of CD5L upon activation and activation- 
dependent induction of posttranslational modifications of a 
resident cell-surface receptor that transiently enables its in- 
teraction with CD5.  However, it appears clear that CD5- 
CD5L interaction requires activation of CDSL-expressing 
cells.  This is  reminiscent of interactions between some of 
the counterreceptors that underlie key T-B cell costimula- 
tory  mechanisms,  including B7-1/B7-2-CD28/CTLA-4 
and CD40-CD40L,  where  the  costimulatory signal is  ex- 
changed between a  newly expressed ligand and a  costitu- 
tively expressed receptor.  Interestingly, B220 + splenocytes 
expressed CD5L after triggering CD3  and CD28, both of 
which  are  restricted  to  T  cells.  This  observation suggests 
that  CD5L  expression on  B  cells requires T  cell-derived 
signals.  The  putative  signals  appear  to  be  distinct  from 
CD40L and IL-4, based on the  observation that blocking 
anti-CD40L  and  anti-IL-4  receptor  mAbs  did  not  alter 
CD5L  expression (data not shown). A  similar observation 
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Figure  8.  Circulating antibodies to Rb IgG detected by ELISA. At 
days 7 and 21, the titers of antibodies of CD5Rg-treated mice were sig- 
nificantly  lower than those in PBS- or CD8Rg-treated mice (*P <0.05). 
Naive (untreated) mice had an average titer of 0.082 -+ 0.020, which was 
considered as background  in the assay. [], PBS; C3, CD8Rg; f-l, CD5Rg. 
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pression of CTLA-4 on B  cells (27). 
Based  on  the  observations  that  deglycosylation  of 
CD5Rg  abrogates  interaction  with  CD5L,  and  that  COS 
cell  derived  CD5Rg  does  not  recognize  CD5L  on  acti- 
vated  splenocytes  (data  not  shown),  it  seems  likely  that 
CD5-CD5L  is either a lectin  type interaction,  or that gly- 
cosylation  of CD5  is  critical  in  providing  the  appropriate 
conformation  to  the  ligand-binding  site.  The  importance 
of lectin  type  interactions  in  leukocyte-endothelial  adhe- 
sion,  mediated by the selectin family of receptors  (28), and 
in  the  adhesion  of cells  to  extracellular  matrix  glycosami- 
noglycans  (GAG),  mediated  by  CD44  (21)  and  other 
GAG-binding  cell-surface  receptors,  is  well  established. 
However, recent work has shown that lectins participate in 
leukocyte  cell-cell  interactions  as  well,  and  that  a  subclass 
ofinmmnoglobulin  receptors, including the B  cell receptor 
CD22  (29), the macrophage receptor sialoadhesin  (30), and 
the  myeloid  cell  antigen  CD33  (31),  behave  primarily  as 
sialic  acid-binding  lectins.  CD22  has  recently  been  pro- 
posed to behave as a costimulatory molecule for both B and 
T  cell activation  (32,  33).  Thus,  CD5-CD5L  may possibly 
extend  the  number of leukocyte  receptor interactions  that 
display  lectin  activity.  Alternatively,  CD5-CD5L  interac- 
tion  may  require  specific  glycosyl  chain-dependent  CD5 
conformation.  It has been demonstrated that attachment of 
a single N-linked oligosaccharide  chain to the extracellular 
domain  of CD2  is  critical  in  conferring  a  ligand-binding 
configuration  (34), and recent results indicate that the same 
holds true for CD22  (35). Additional work will be required 
to  determine  the  nature  of CD5  glycosylation in T  and B 
ceils, and whether the activation state oflymphocytes alters 
the  composition  of CD5-associated  glycans  in  a  manner 
that influences its ability to recognize ligand. 
The  CD5  ligand  identified  in  the  present  study appears 
to be distinct from CD72.  First, binding of CD5Rg to rest- 
ing splenocytes is not observed,  despite  constitutive  CD72 
expression on T  and B  cells. Second,  CD5Rg binds to acti- 
vated  T  cell  clones  that  do  not  express  detectable  CD72 
(data not shown).  Third,  a soluble  CD72  fusion protein as 
well as an anti-CD72 mAb that has been suggested to block 
CD5--CD72  interaction  failed  to  inhibit  CD5Rg  binding 
to activated splenocytes and T  cell clones.  Finally,  CD5Rg 
was  observed  to  immunoprecipitate  a  35-37-kD  protein 
from  lysates  of activated  splenocytes  and  T  cell  clones, 
which provides a candidate for CD5L, However, immuno- 
precipitation  of the 35-37-kD protein by CD5Rg does not 
prove that this species is itself CD5L,  since our data do not 
exclude  the  possibility  that  it  may be  associated  with  an- 
other molecule  that serves as the actual ligand.  Elucidation 
of the identity of CD5L will require further investigation. 
The  observation  that  CD5  and  its  ligands  are  both 
present in T  and B  cells supports a role for CD5-CD5L  in- 
teraction in T-B cell costimulation during a T  cell-depen- 
dent  immune  response.  Experimental  MGN  provides  a 
suitable  model  to  study  a  classic  T  cell-dependent,  anti- 
body-mediated immune response to rabbit IgG (19, 20).  In 
this  model,  antibody-antigen  complexes  are  deposited  in 
glomeruli,  leading  to  the  development  of  membranous 
glomerulonephritis  with  well-defined  morphologic  lesions 
(19, 20). The disease does not develop in athymic mice and 
is  prevented  by blocking  the  CD40-CD40L  pathway  of 
T-B  cell costimulation  (20).  Our present results show that 
treatment  with  CD5Rg  significantly  reduces  the  levels  of 
circulating mouse  anti-rabbit  IgG antibodies,  indicative  of 
the autologous immune response, and prevents the deposi- 
tion  of immune  complexes.  The inhibition  of the  autolo- 
gous immune response was sufficient to allow clearance  of 
immune  complexes  by  glomerular  visceral  epithelial  and 
possibly mesangial  cells,  thereby  preventing  accumulation 
of immune  deposits  in  the  peripheral  glomerular  capillary 
walls. 
Taken together,  our results demonstrate  the existence of 
an  inducible  CD5  ligand  that  is  distinct  from  CD72,  and 
provide  evidence  that  CDS-CD5L  interaction  may play a 
significant  role  in  T-B  cell  costimulation  in  vivo.  These 
observations suggest that CDS-CDSL provides a new path- 
way in lymphocyte activation whose role relative to that of 
CD28/CTLA4-B7.1/B7.2  and  CD40-CD40L  can  now 
be explored. 
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